Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IONS Ionis Pharmaceuticals, Inc

盘前交易 03-24 05:37:08 EDT

70.79

-0.20

-0.28%

最高73.15	最低70.67	成交量219.81万
今开72.25	昨收70.99	日振幅3.49%
总市值116.94亿	流通市值116.10亿	总股本1.65亿
成交额1.57亿	换手率1.34%	流通股本1.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":70.79,"timestamp":1774296000000,"preClose":70.99,"halted":0,"volume":2198127,"delay":0,"changeRate":-0.002817298211015476,"floatShares":164000000,"shares":165192011,"eps":-2.38,"marketStatus":"盘前交易","change":-0.2,"latestTime":"03-24 05:37:08 EDT","open":72.25,"high":73.15,"low":70.67,"amount":156734170.52577,"amplitude":0.034934,"askPrice":80.81,"askSize":100,"bidPrice":70.04,"bidSize":33,"shortable":3,"etf":0,"ttmEps":-2.38,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774359000000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":70.79,"postHourTrading":{"tag":"盘后","latestPrice":70.79,"preClose":70.79,"latestTime":"16:49 EDT","volume":90099,"amount":6378109.93,"timestamp":1774298981398,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.8746696303754337,"impliedVol":0.4574,"impliedVolPercentile":0.556},"requestUrl":"/m/hq/s/IONS","defaultTab":"news","newsList":[{"id":"1158180966","title":"Ionis制药宣布亚历山大病新药Zilganersen获FDA优先审评资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1158180966","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158180966?lang=zh_cn&edition=full","pubTime":"2026-03-23 19:00","pubTimestamp":1774263619,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc. 近日宣布，其针对亚历山大病（AxD）研发的新药Zilganersen的新药申请（NDA）已获得美国食品药品监督管理局（FDA）的优先审评资格。这一重要进展意味着该药物的审评周期将有望缩短，为患有此种罕见神经系统疾病的患者带来新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1189414337","title":"Ionis制药公司获FDA设定处方药用户费用法案目标行动日期为2026年6月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=1189414337","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189414337?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:03","pubTimestamp":1772107408,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已为Ionis制药公司（Ionis Pharmaceuticals, Inc）设定了一项关键监管节点——根据处方药用户费用法案（Pdufa），其目标行动日期定为2026年6月30日。\n这一日期标志着FDA完成对该公司相关药物申请审查的最终期限。该时间表的确定，为Ionis制药的研发进程提供了明确的监管时间框架，也预示着其新药审批流程进入倒计时阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1164552946","title":"异动解读 | 预测2026年收入低于预期，Ionis Pharmaceuticals盘前大跌9.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164552946","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164552946?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:40","pubTimestamp":1772023241,"startTime":"0","endTime":"0","summary":"生物制药公司Ionis Pharmaceuticals  今日盘前股价大幅下跌9.54%，引起了市场的广泛关注。消息面上，该公司发布了最新的财务预测，预计2026年收入将在8亿至8.25亿美元之间，这一数字低于华尔街分析师平均预期的9.02亿美元。市场分析认为，对未来收入增长的保守预期是导致投资者信心受挫、股价在盘前交易时段承压下跌的主要原因。公司旗下遗传疾病药物Tryngolza在第四季度销售额达到5000万美元，环比增长56%，显示出良好的产品势头，但未能抵消市场对远期财务表现的担忧。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IONS"],"gpt_icon":0},{"id":"1173104180","title":"财报前瞻｜Ionis Pharmaceuticals, Inc本季度营收预计增13.44%，欧洲获批与里程碑进度牵动预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1173104180","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173104180?lang=zh_cn&edition=full","pubTime":"2026-02-18 10:47","pubTimestamp":1771382875,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc将于2026年02月25日发布最新季度财报，市场关注商业板块增速、管线里程碑兑现与费用节奏的平衡。市场一致预期本季度Ionis Pharmaceuticals, Inc营收预计为1.56亿美元，同比增加13.44%；调整后每股收益预计为-1.32美元，同比下降17.63%；息税前利润预计为-2.10亿美元，同比下降19.11%；公司上季度并未在公开口径给出明确的季度营收或EPS指引。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Ionis Pharmaceuticals, Inc本季度营收预计增13.44%，欧洲获批与里程碑进度牵动预期","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"gpt_icon":0},{"id":"1191518855","title":"Ionis Pharmaceuticals, Inc 有望获得1500万美元里程碑付款及高达30%的净销售额分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1191518855","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191518855?lang=zh_cn&edition=full","pubTime":"2026-01-21 20:04","pubTimestamp":1768997079,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc 近日迎来重大利好消息。根据最新合作协议条款，该公司已具备资格获取一笔高达1500万美元的里程碑付款。更值得关注的是，其特许权使用费结构将采用分层模式，最高可达产品净销售额的30%。这一商业安排凸显了Ionis Pharmaceuticals核心产品的市场潜力。对于Ionis Pharmaceuticals而言，这笔潜在收益将为其研发管线注入新的资金支持，同时强化公司在罕见病和精准医疗领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1145314898","title":"渤健公司获欧盟委员会批准Spiranza®高剂量方案用于脊髓性肌萎缩症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1145314898","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145314898?lang=zh_cn&edition=full","pubTime":"2026-01-13 00:11","pubTimestamp":1768234293,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准渤健公司针对脊髓性肌萎缩症的Spiranza®（Nusinersen）高剂量治疗方案。这一监管里程碑标志着该疗法在欧盟市场获得重要拓展，为患者群体提供更具灵活性的用药选择。\n此次获批的高剂量方案将进一步提升药物在临床实践中的应用价值，凸显渤健公司在神经科学治疗领域持续创新的战略布局。监管机构的认可也为该疗法在更广泛患者群体中的使用铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","BK4588","LU0109394709.USD","LU0889565916.HKD","BK4532","IE00B19Z9Z06.USD","BK4585","IE00B19Z9P08.USD","IONS","BK4533","LU0234570918.USD","LU0320765992.SGD","BK4139","IE00B894F039.SGD"],"gpt_icon":0},{"id":"1137439537","title":"Ionis合作伙伴葛兰素史克公布Bepirovirsen三期研究B-Well 1和B-Well 2积极顶线结果 该药物有望成为慢性乙肝首创疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1137439537","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137439537?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:18","pubTimestamp":1767770330,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc的合作伙伴葛兰素史克宣布，其针对慢性乙型肝炎的潜在首创药物Bepirovirsen，在三期临床研究B-Well 1和B-Well 2中取得了积极的顶线结果。这项关键进展标志着该疗法在追求功能性治愈慢性乙肝的道路上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1172421919","title":"Ionis宣布拟议可转换债券发行以再融资2026年可转换债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1172421919","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172421919?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:25","pubTimestamp":1763573107,"startTime":"0","endTime":"0","summary":"11月12日消息 - Ionis Pharmaceuticals Inc ::*IONIS宣布拟议可转换债券发行以再融资2026年可转换债券*IONIS PHARMACEUTICALS INC - 将发行7亿美元可转换债券，到期时间为2030年*IONIS PHARMACEUTICALS INC - 授予额外7000万美元债券的选择权","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1158847363","title":"Dawnzera™（Donidalorsen）获得CHMP积极意见，推荐在欧盟批准治疗遗传性血管水肿（HAE）","url":"https://stock-news.laohu8.com/highlight/detail?id=1158847363","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158847363?lang=zh_cn&edition=full","pubTime":"2025-11-14 20:01","pubTimestamp":1763121688,"startTime":"0","endTime":"0","summary":"Dawnzera™（Donidalorsen）获得CHMP的积极意见，建议在欧盟批准用于治疗遗传性血管水肿（HAE）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1159503918","title":"Ionis Pharmaceuticals Inc：定价7亿美元的2030年到期0.00%可转换高级债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1159503918","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159503918?lang=zh_cn&edition=full","pubTime":"2025-11-13 13:40","pubTimestamp":1763012431,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals Inc：定价7亿美元的2030年到期0.00%可转换高级债券","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1191555721","title":"Ionis Pharmaceuticals股价在盘后上涨3.2%；宣布拟定可转换债券发行以再融资2026年可转换票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1191555721","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191555721?lang=zh_cn&edition=full","pubTime":"2025-11-12 05:38","pubTimestamp":1762897106,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals股价在盘后上涨3.2%；宣布拟定可转换债券发行以再融资2026年可转换票据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1172347027","title":"Ionis Pharmaceuticals：预计产品REV将迎来增长，新增合作伙伴REV助力公司在2028年实现现金流持平","url":"https://stock-news.laohu8.com/highlight/detail?id=1172347027","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172347027?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:11","pubTimestamp":1761736303,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals：预计产品REV将迎来增长，新增合作伙伴REV助力公司在2028年实现现金流持平","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2518070452","title":"Ionis Pharmaceuticals, Inc.盘中异动 大幅下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518070452","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518070452?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:53","pubTimestamp":1741632820,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时53分，Ionis Pharmaceuticals, Inc.股票出现波动，股价快速下挫5.00%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025340abf37261&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025340abf37261&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"2516309676","title":"Ionis Pharmaceuticals, Inc.盘中异动 快速拉升5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516309676","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516309676?lang=zh_cn&edition=full","pubTime":"2025-03-01 04:34","pubTimestamp":1740774847,"startTime":"0","endTime":"0","summary":"北京时间2025年03月01日04时34分，Ionis Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.01%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010434079896c4aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503010434079896c4aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2513270227","title":"Ionis Pharmaceuticals, Inc.2024财年实现净利润-4.54亿美元，同比减少24.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513270227","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513270227?lang=zh_cn&edition=full","pubTime":"2025-02-23 00:00","pubTimestamp":1740240042,"startTime":"0","endTime":"0","summary":"2月23日，Ionis Pharmaceuticals, Inc.公布财报，公告显示公司2024财年净利润为-4.54亿美元，同比减少24.04%；其中营业收入为7.05亿美元，同比减少10.53%，每股基本收益为-3.03美元。机构评级：截至2025年2月23日，当前有22家机构对Ionis Pharmaceuticals, Inc.目标价做出预测，其中目标均价为58.23美元，其中最低目标价为37.00美元，最高目标价为78.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223000052a24fcc08&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250223000052a24fcc08&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS"],"gpt_icon":0},{"id":"2512048389","title":"Ionis Pharmaceuticals, Inc.盘中异动 快速上涨7.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512048389","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512048389?lang=zh_cn&edition=full","pubTime":"2025-02-19 22:31","pubTimestamp":1739975495,"startTime":"0","endTime":"0","summary":"北京时间2025年02月19日22时31分，Ionis Pharmaceuticals, Inc.股票出现异动，股价大幅拉升7.20%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.15%。其相关个股中，Osr Holdings, Inc.、Aditxt, Inc.、Citius Pharmaceuticals, Inc.涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Chemomab Therapeutics Ltd较为活跃，换手率分别为206.33%、202.22%、65.58%，振幅较大的相关个股有Osr Holdings, Inc.、Azitra Inc、2Seventy Bio, Inc.，振幅分别为21.86%、11.29%、7.53%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223135abd4fe11&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250219223135abd4fe11&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1151005128","title":"异动解读 | Ionis Pharmaceuticals盘前大涨6.42%,2024Q4业绩超预期引起看涨预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1151005128","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151005128?lang=zh_cn&edition=full","pubTime":"2025-02-19 21:52","pubTimestamp":1739973160,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc(IONS)今日盘前股价大涨6.42%,引起了市场广泛关注。\n\n令市场看涨的主因是IONS公布了2024年第四季度业绩,财报数据优于预期。具体来看,第四季度销售额达到2.27亿美元,高于分析师预期的1.376亿美元;同时亏损也较预期的1.12美元/股好,为0.66美元/股。\n\n分析师对公司2025年业绩也持乐观态度。IONS管理层预计2025年全年营收将超过6亿美元,而分析师预计营收将达到6.76亿美元。截至2024年底,IONS持有现金及等价物23亿美元,预计2025年底仍将有约17亿美元的现金储备。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IONS"],"gpt_icon":0},{"id":"1103110364","title":"Ionis制药2024年第四季度GAAP每股亏损$(0.66)优于预期$(1.10)，销售额$2.27亿高于预期$1.376亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1103110364","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103110364?lang=zh_cn&edition=full","pubTime":"2025-02-19 20:07","pubTimestamp":1739966871,"startTime":"0","endTime":"0","summary":"Ionis制药公司报告季度每股亏损$，优于分析师普遍预期的$，提升了40%。与去年同期每股亏损$相比，这一数字大幅下降了1000%。以上内容来自Benzinga Earnings专栏，原文如下：Ionis Pharmaceuticals  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 40 percent. This is a 1000 percent decrease over losses of $ per share from the same period last year.  The company reported quarterly sales of $227.00 million which beat the analyst consensus estimate of $137.60 million by 64.97 percent.  This is a 30.15 percent decrease over sales of $3","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Ionis制药2024年第四季度GAAP每股亏损$(0.66)优于预期$(1.10)，销售额$2.27亿高于预期$1.376亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"gpt_icon":0},{"id":"2509255649","title":"Ionis Pharmaceuticals, Inc.盘中异动 快速上涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509255649","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509255649?lang=zh_cn&edition=full","pubTime":"2025-02-06 04:21","pubTimestamp":1738786902,"startTime":"0","endTime":"0","summary":"北京时间2025年02月06日04时21分，Ionis Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.03%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为2.26%。其相关个股中，Immatics N V C/Wts 01/07/2025 、Invivyd, Inc.、Transcode Therapeutics, Inc.涨幅较大，Pasithea Therapeutics Corp.、Transcode Therapeutics, Inc.、Oragenics Inc.较为活跃，换手率分别为4679.47%、2428.06%、1773.50%，振幅较大的相关个股有Oragenics Inc.、Transcode Therapeutics, Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为132.24%、99.51%、87.50%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206042142abc3c5f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250206042142abc3c5f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2505049934","title":"Ionis Pharmaceuticals, Inc.盘中异动 快速上涨5.11%报34.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505049934","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505049934?lang=zh_cn&edition=full","pubTime":"2025-01-24 01:11","pubTimestamp":1737652309,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日01时11分，Ionis Pharmaceuticals, Inc.股票出现异动，股价大幅拉升5.11%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Dogwood Therapeutics, Inc.、Nutriband Inc C/Wts 、Conduit Pharmaceuticals Inc C/Wts 22/09/2028涨幅较大，Hepion Pharmaceuticals, Inc.、Dogwood Therapeutics, Inc.、Quoin Pharmaceuticals Ltd较为活跃，换手率分别为3681.80%、3081.62%、674.61%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Nutriband Inc C/Wts 、Conduit Pharmaceuticals Inc C/Wts 22/09/2028，振幅分别为246.43%、65.78%、62.70%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals Inc是研发新型药物反义技术的领头研发者。Ionis和阿斯利康将于2024年推出多发性神经病药物Wainua。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501240111499870d898&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501240111499870d898&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IONS","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ionis.com","stockEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":-0.1486},{"period":"3month","weight":-0.1188},{"period":"6month","weight":0.1071},{"period":"1year","weight":1.151},{"period":"ytd","weight":-0.1052}],"compareEarnings":[{"period":"1week","weight":-0.0204},{"period":"1month","weight":-0.0494},{"period":"3month","weight":-0.0474},{"period":"6month","weight":-0.0087},{"period":"1year","weight":0.1621},{"period":"ytd","weight":-0.0389}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司于1989年在加利福尼亚州注册成立，并于1991年1月将公司注册州变更为特拉华州。该公司花了三十年时间开拓RNA靶向药物，并已发展成为一家完全整合的商业阶段生物技术公司，拥有七种已上市药物，并拥有横跨神经病学、心脏代谢疾病和其他患者高需求领域的强大管道。它继续通过独立和合作开发推进下一代RNA靶向技术，为患有严重疾病的患者提供创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.020204},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.015383},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.037091},{"month":4,"riseRate":0.4,"avgChangeRate":0.018094},{"month":5,"riseRate":0.4,"avgChangeRate":-0.049558},{"month":6,"riseRate":0.8,"avgChangeRate":0.059464},{"month":7,"riseRate":0.8,"avgChangeRate":0.041363},{"month":8,"riseRate":0.5,"avgChangeRate":0.012224},{"month":9,"riseRate":0.5,"avgChangeRate":0.051342},{"month":10,"riseRate":0.2,"avgChangeRate":-0.026479},{"month":11,"riseRate":0.6,"avgChangeRate":0.097251},{"month":12,"riseRate":0.4,"avgChangeRate":0.002194}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}